Skip to main content

Statera Biopharma, Inc. (STAB)

NASDAQ: STAB · IEX Real-Time Price · USD
3.18
-0.04 (-1.24%)
After-hours:Oct 15, 2021 7:47 PM EDT
3.22
0.38 (13.38%)
At close: Oct 15, 4:00 PM
Market Cap103.35M
Revenue (ttm)43,645
Net Income (ttm)-2.64M
Shares Out15.47M
EPS (ttm)-0.53
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,518,275
Open2.99
Previous Close2.84
Day's Range2.85 - 3.85
52-Week Range2.11 - 10.97
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About STAB

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical pro...

IndustryBiotechnology
IPO DateJul 21, 2006
Employees18
Stock ExchangeNASDAQ
Ticker SymbolSTAB
Full Company Profile

Financial Performance

In 2020, STAB's revenue was $262,942, a decrease of -76.38% compared to the previous year's $1.11 million. Losses were -$2.40 million, -9.39% less than in 2019.

Financial Statements

News

Statera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma Conference

FORT COLLINS, Colo., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restorat...

1 week ago - GlobeNewsWire

Statera Biopharma Announces CEO Mike Handley to Speak During Virtual B & T Cell-Mediated Autoimmune Disease Drug Deve...

FORT COLLINS, Colo., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restorat...

1 week ago - GlobeNewsWire

Statera Biopharma, Inc. to Participate in the Cantor Virtual Global Healthcare Conference

FORT COLLINS, Colo., Sept. 21, 2021 /PRNewswire/ -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration...

3 weeks ago - PRNewsWire

Statera BioPharma, Inc. to Ring Nasdaq Stock Market Closing Bell

FORT COLLINS, Colo., Sept. 2, 2021 /PRNewswire/ -- Statera BioPharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration ...

1 month ago - PRNewsWire

What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease...

Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions involving Cleveland BioLabs and ImQuest Li...

1 month ago - Benzinga

Statera BioPharma: The Ticker Formerly Known as CBLI

On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets.  This change in name comes ...

1 month ago - Benzinga

Statera BioPharma, Inc. Provides Update on Integration of ImQuest

FORT COLLINS, Colo., Sept. 1, 2021 /PRNewswire/ -- Statera BioPharma (NASDAQ: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and ho...

1 month ago - PRNewsWire

Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."

FORT COLLINS, Colo., Aug. 31, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeos...

1 month ago - PRNewsWire

Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeos...

2 months ago - PRNewsWire

Cytocom, Inc. Reports Second Quarter 2021 Financial Results

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce ...

2 months ago - PRNewsWire

Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement

FORT COLLINS, Colo., Aug. 12, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeos...

2 months ago - PRNewsWire

Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference

FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeos...

2 months ago - PRNewsWire

Cytocom, Inc. to Report Second Quarter 2021 Financial Results

FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeos...

2 months ago - PRNewsWire

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19

FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc.  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeost...

2 months ago - PRNewsWire

Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs

FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeosta...

2 months ago - PRNewsWire

Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing

FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured a...

2 months ago - PRNewsWire

Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532

The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Geno...

6 months ago - Accesswire

SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations

NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o...

Other symbols:TLRY
7 months ago - PRNewsWire

Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.

FORT COLLINS, Colo. and BUFFALO, N.Y., Feb. 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune sy...

7 months ago - PRNewsWire

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - CBLI, IPHI, CBMG, WTRE, CIT

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cleveland BioLabs, Inc. (NASDAQ: CBLI) concerning pote...

9 months ago - PRNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Investigates Cleveland BioLabs, Inc.

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cleveland BioLabs, Inc. ("CBLI" or the ...

11 months ago - PRNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Cleveland BioLabs, Inc.

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cleveland BioLabs, Inc. (NASDAQ: CBLI) and its board of directors concerning the proposed ...

11 months ago - PRNewsWire

Cleveland BioLabs Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Cleveland...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Cytocom, Inc. is fair to Cleveland ...

11 months ago - Business Wire